Being a voice for patients: a Cancer Drugs Fund update
NHS England confirm that two blood cancer treatments, Ibrutinib and Brentuximab, will continue to be available to NHS patients via the Cancer Drugs Fund. The treatments were delisted from the CDF in September, but have been readmitted following negotiations between NHS England and the drugs’ manufacturers.
We're delighted to announce that NHS England have announced that two blood cancer treatments will continue to be available to NHS patients via the Cancer Drugs Fund. The treatments were delisted from the CDF in September, but have been readmitted following negotiations between NHS England and the drugs’ manufacturers.
A huge thank you to everyone who signed the petition and the alliance of blood cancer charities who campaigned with us to reverse the delisting of these vital drugs and find an alternative solution. Part of our campaign included writing an open letter that we sent to the Prime Minister and Secretary of State for Health, which was published in The Times. Read it here >
The drug indications readmitted onto the CDF are:
- Ibrutinib for relapsed/refractory Chronic Lympocytic Leukaemia and for relapsed/refractory Mantle Cell Lymphoma
- Brentuximab for refractory systemic anaplastic lymphoma and for relapsed or refractory CD30+ Hodgkin’s lymphoma
This marks a significant development for patients, with access to these medicines now secured for NHS patients. Ibrutinib and brentuximab are highly effective, and are regarded by the clinical community as the leading treatment option for these patient populations.
Diana Jupp, Director of Patient Experience at Bloodwise said:
“This is terrific news for many blood cancer patients. There was complete dismay amongst clinicians and patients when these was initially delisted in September. We welcome the negotiations undertaken by NHS England and the drug manufacturers that will allow NHS patients to continue to access them.
“We now need to turn our attention to the remaining effective blood cancer drugs that are still unavailable for NHS patients– we hope that either through continued negotiations or through the new assessment process due to be launched next year, we can ensure blood cancer patients have access to all effective treatments.”